目的 研究復(fù)方蒲芩膠囊聯(lián)合阿奇霉素膠囊治療肺炎的臨床療效。方法 選取2015年4月—2017年4月天門(mén)市第一人民醫(yī)院收治的肺炎患者120例作為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組口服阿奇霉素膠囊，1粒/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服復(fù)方蒲芩膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療10 d。觀察兩組的臨床療效，比較兩組的臨床癥狀消失時(shí)間和血清炎性因子水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.33%、93.33%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組咳嗽消失時(shí)間、白細(xì)胞恢復(fù)正常時(shí)間、體溫恢復(fù)正常時(shí)間和啰音消失時(shí)間均短于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組超敏C-反應(yīng)蛋白（hs-CRP）、白細(xì)胞計(jì)數(shù)、中性粒細(xì)胞數(shù)水平顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清炎性因子水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方蒲芩膠囊聯(lián)合阿奇霉素膠囊治療肺炎具有較好的臨床療效，可改善臨床癥狀，調(diào)節(jié)炎性因子水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical efficacy of Compound Puqin Capsules combined with Azithromycin Capsules in treatment of pneumonia. Methods Patients (120 cases) with pneumonia in Tianmen First People's Hospital from April 2015 to April 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Azithromycin Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Compound Puqin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and the clinical symptoms disappeared time and the level of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.33% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, the cough disappeared time, the white blood cell count returned to normal time, the body temperature returned to normal time, and the rale disappear time in the treatment group were shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of hs-CRP, white blood cell count, and neutrophil count in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the levels of serum inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Compound Puqin Capsules combined with Azithromycin Capsules has clinical curative effect in treatment of pneumonia, can improve clinical symptoms, and regulate the level of inflammatory factors, with good safety, which has a certain clinical application value.